Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
The procedures have been performed by Dr. Kaushal Pandey at P.D. Hinduja Hospital in Mumbai, India
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
About 250+ women riders participate in the awareness ride where free breast screening camp were conducted
The incubator anchored at the company's global headquarters in Raleighla launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm
Bolstering neuroscience push with late-stage Tourette therapy
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
